Investigational Oral LSD Tablet Meets Phase III Endpoints in Anxiety and Depression Studies

DT120, an investigational orally disintegrating tablet formulation of the psychedelic compound lysergide (LSD), met the primary endpoints in a pair of Phase III clinical trials for generalized anxiety disorder (GAD) and major depressive disorder.

What's Hot

New York Giants on Verge of NFC East Dominance as Philadelphia Eagles Continue to Falter

Labubu Mania Shows Signs of Cooling as Collectors Move on to New Trends

Wendy’s Launches Retro Mobile RPG WendyQuest with Real Fries Giveaway

Investigational Oral LSD Tablet Meets Phase III Endpoints in Anxiety and Depression Studies

Advancing Breast Cancer Care and Psychedelic Treatments for Depression

Archaeological Discovery Pushes Back Cannabis Use by Millennia

Federal Regulators Decertify Two Surprise Billing Arbitrators Citing Performance Failures

Texas Democrats Capture Statewide Offices, Confronting Urgent Healthcare Reform

Johnson & Johnson’s Rybrevant Faspro Gains Accelerated FDA Nod for Head and Neck Squamous Cell Carcinoma

Readers Respond: Autism Diagnosis, Masking Research, and the Limits of Labels

Advancing Breast Cancer Care and Psychedelic Treatments for Depression

Archaeological Discovery Pushes Back Cannabis Use by Millennia

Federal Regulators Decertify Two Surprise Billing Arbitrators Citing Performance Failures

Texas Democrats Capture Statewide Offices, Confronting Urgent Healthcare Reform

What's Hot

Investigational Oral LSD Tablet Meets Phase III Endpoints in Anxiety and Depression Studies

Also Read

Keep Reading

Subscribe to Updates